Advertisement

Urinary nerve growth factor: a biomarker for detrusor overactivity in children? A meta-analysis and trail sequential analysis

  • Changkai DengEmail author
  • Wei Zhang
  • Qiang Peng
  • Xianliang Hu
  • Maoxian Li
  • Li Gao
  • Juan Xu
  • Jing Su
  • Xue Xia
Original Article
  • 4 Downloads

Abstract

Purpose

Based on, previously, a systematic review, urinary nerve growth factor (NGF) has emerged as one potentially noninvasive biomarker for detrusor overactivity (DO) in adults. We performed this systematic review to explore if NGF is a biomarker for DO in children.

Methods

A literature search was conducted in PubMed, Embase, Web of science, and Cochrane Library. Copies of all relevant articles were retrieved for quality assessment and data abstraction by two reviewers. Primary outcome was pooled standardized mean difference (SMD) for NGF/Cr (NGF normalized to urine creatinine) level between DO group and controls.

Results

Three case–control studies published from 2012 to 2016 were included with 74 patients and 70 controls. Children with DO had a significant higher baseline urinary NGF/Cr level compared to controls (SMD = 2.48, 95%CI = 0.85–4.10, P < 0.01). After treatment, the level of NGF/Cr decreased significantly compared to baseline level at 6th month time points (SMD = 0.94, 95%CI = 0.03–1.86, P = 0.04). We calculated the required information size to 99 patients for comparison of urinary NGF/Cr level between DO and controls by trail sequential analysis (TSA).

Conclusion

Based on this systematic review, NGF/Cr may be a noninvasive biomarker for DO in children in the future. However, based on TSA, more original studies are needed to clarify the role of NGF/Cr in the biomarker effect.

Keywords

Biomarker Children Detrusor overactivity Systematic review Trail sequential analysis Urinary nerve growth factor 

Notes

Funding

This work was supported by Health and Family Planning Commission of Sichuan Province Research Projects (Project no.:18PJ038).

Compliance with ethical standards

Conflict of interest

The authors have no relevant financial relationships to the article to disclose.

Supplementary material

383_2019_4448_MOESM1_ESM.png (9 kb)
Supplementary material 1 (PNG 9 KB)
383_2019_4448_MOESM2_ESM.png (25 kb)
Supplementary material 2 (PNG 25 KB)
383_2019_4448_MOESM3_ESM.png (10 kb)
Supplementary material 3 (PNG 9 KB)
383_2019_4448_MOESM4_ESM.png (270 kb)
Supplementary material 4 (PNG 269 KB)
383_2019_4448_MOESM5_ESM.png (210 kb)
Supplementary material 5 (PNG 210 KB)
383_2019_4448_MOESM6_ESM.docx (11 kb)
Supplementary material 6 (DOCX 11 KB)

References

  1. 1.
    Austin PF, Bauer SB, Bower W (2014) The standardization of terminology of lower urinary tract function in children and adolescents: update report from the Standardization Committee of the International Children’s Continence Society. J Urol 191:1863–1865 e1813CrossRefGoogle Scholar
  2. 2.
    Austin PF, Bauer SB, Bower W (2016) The standardization of terminology of lower urinary tract function in children and adolescents: Update report from the standardization committee of the International Children’s Continence Society. Neurourol Urodyn 35:471–481CrossRefGoogle Scholar
  3. 3.
    Franco I (2016) Overactive bladder in children. Nat Rev Urol 13:520–532CrossRefGoogle Scholar
  4. 4.
    Stone JJ, Rozzelle CJ, Greenfield SP (2010) Intractable voiding dysfunction in children with normal spinal imaging: predictors of failed conservative management. Urology 75:161–165CrossRefGoogle Scholar
  5. 5.
    Fitzgerald MP, Thom DH, Wassel-Fyr C (2006) Childhood urinary symptoms predict adult overactive bladder symptoms. J Urol 175:989–993CrossRefGoogle Scholar
  6. 6.
    Bael A, Lax H, de Jong TP (2008) The relevance of urodynamic studies for Urge syndrome and dysfunctional voiding: a multicenter controlled trial in children. J Urol 180:1486–1493CrossRefGoogle Scholar
  7. 7.
    Cartwright R, Afshan I, Derpapas A (2011) Novel biomarkers for overactive bladder. Nat Rev Urol 8:139–145CrossRefGoogle Scholar
  8. 8.
    Chung SD, Liu HT, Lin H (2011) Elevation of serum c-reactive protein in patients with OAB and IC/BPS implies chronic inflammation in the urinary bladder. Neurourol Urodyn 30:417–420CrossRefGoogle Scholar
  9. 9.
    Vijaya G, Cartwright R, Bhide A (2016) Reliability and validity of urinary nerve growth factor measurement in women with lower urinary tract symptoms. Neurourol Urodyn 35:944–948CrossRefGoogle Scholar
  10. 10.
    Liu HT, Kuo HC (2009) Urinary nerve growth factor levels are elevated in patients with overactive bladder and do not significantly increase with bladder distention. Neurourol Urodyn 28:78–81CrossRefGoogle Scholar
  11. 11.
    Liu HT, Kuo HC (2008) Urinary nerve growth factor level could be a potential biomarker for diagnosis of overactive bladder. J Urol 179:2270–2274CrossRefGoogle Scholar
  12. 12.
    Pennycuff JF, Schutte SC, Hudson CO (2017) Urinary neurotrophic peptides in postmenopausal women with and without overactive bladder. Neurourol Urodyn 36:740–744CrossRefGoogle Scholar
  13. 13.
    Rachaneni S, Arya P, Latthe P (2013) Urinary nerve growth factor: a biomarker of detrusor overactivity? A systematic review. Int Urogynecol J 24:1603–1609CrossRefGoogle Scholar
  14. 14.
    Qu HC, Yan S, Zhang XL (2014) Urinary nerve growth factor levels could be a biomarker for overactive bladder symptom: a meta-analysis. Genet Mol Res 13:8609–8619CrossRefGoogle Scholar
  15. 15.
    Moher D, Liberati A, Tetzlaff J (2009) Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med 6:e1000097CrossRefGoogle Scholar
  16. 16.
    Margulis AV, Pladevall M, Riera-Guardia N (2014) Quality assessment of observational studies in a drug-safety systematic review, comparison of two tools: the Newcastle-Ottawa Scale and the RTI item bank. Clin Epidemiol 6:359–368CrossRefGoogle Scholar
  17. 17.
    Wetterslev J, Jakobsen JC, Gluud C (2017) Trial sequential analysis in systematic reviews with meta-analysis. BMC Med Res Methodol 17:39CrossRefGoogle Scholar
  18. 18.
    Kulinskaya E, Wood J (2014) Trial sequential methods for meta-analysis. Res Synth Methods 5:212–220CrossRefGoogle Scholar
  19. 19.
    Higgins JP, Whitehead A, Simmonds M (2011) Sequential methods for random-effects meta-analysis. Stat Med 30:903–921CrossRefGoogle Scholar
  20. 20.
    Oktar T, Kocak T, Oner-Iyidogan Y (2013) Urinary nerve growth factor in children with overactive bladder: a promising, noninvasive and objective biomarker. J Pediatr Urol 9:617–621CrossRefGoogle Scholar
  21. 21.
    Ozdemir K, Dincel N, Berdeli A (2016) Can urinary nerve growth factor and brain-derived neurotrophic factor be used in the diagnosis and follow-up of voiding dysfunction in children? Urol J 13:2690–2696Google Scholar
  22. 22.
    Korzeniecka-Kozerska A, Wasilewska A (2015) Urinary nerve growth factor in patients with detrusor overactivity. Ir J Med Sci 184:737–743CrossRefGoogle Scholar
  23. 23.
    Fukui S, Aoki K, Morizawa Y (2017) Urinary nerve growth factor can predict therapeutic efficacy in children with overactive bladder. Urology 103:214–217CrossRefGoogle Scholar
  24. 24.
    Kuo HC, Liu HT, Chancellor MB (2010) Can urinary nerve growth factor be a biomarker for overactive bladder?. Rev Urol 12:e69–e77Google Scholar
  25. 25.
    Seth JH, Sahai A, Khan MS (2013) Nerve growth factor (NGF): a potential urinary biomarker for overactive bladder syndrome (OAB)? BJU Int 111:372–380CrossRefGoogle Scholar
  26. 26.
    Kim SW, Im YJ, Choi HC (2014) Urinary nerve growth factor correlates with the severity of urgency and pain. Int Urogynecol J 25:1561–1567CrossRefGoogle Scholar
  27. 27.
    Ochodnicky P, Cruz CD, Yoshimura N (2012) Neurotrophins as regulators of urinary bladder function. Nat Rev Urol 9:628–637CrossRefGoogle Scholar
  28. 28.
    Liu HT, Chen CY, Kuo HC (2011) Urinary nerve growth factor in women with overactive bladder syndrome. BJU Int 107:799–803CrossRefGoogle Scholar
  29. 29.
    Liu HT, Chen CY, Kuo HC (2010) Urinary nerve growth factor levels in overactive bladder syndrome and lower urinary tract disorders. J Formos Med Assoc 109:862–878CrossRefGoogle Scholar
  30. 30.
    Liu HT, Chancellor MB, Kuo HC (2009) Decrease of urinary nerve growth factor levels after antimuscarinic therapy in patients with overactive bladder. BJU Int 103:1668–1672CrossRefGoogle Scholar
  31. 31.
    Ergin G, Kibar Y, Ebiloglu T (2016) The role of urinary nerve growth factor for the diagnosis and assessment of the biofeedback success in children with dysfunctional voiding. J Pediatr Urol 12:118 e111–e116CrossRefGoogle Scholar

Copyright information

© Springer-Verlag GmbH Germany, part of Springer Nature 2019

Authors and Affiliations

  • Changkai Deng
    • 1
    Email author
  • Wei Zhang
    • 1
  • Qiang Peng
    • 1
  • Xianliang Hu
    • 1
  • Maoxian Li
    • 1
  • Li Gao
    • 1
  • Juan Xu
    • 1
  • Jing Su
    • 1
  • Xue Xia
    • 1
  1. 1.Department of Pediatric SurgeryChengdu Women’s and Children’s Central Hospital of Chongqing Medical UniversityChengduChina

Personalised recommendations